首页> 美国卫生研究院文献>Cancers >Classical and Non-Classical Progesterone Signaling in Breast Cancers
【2h】

Classical and Non-Classical Progesterone Signaling in Breast Cancers

机译:乳腺癌中古典和非古典孕酮信号传导

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Much emphasis is placed on estrogen (E2) and estrogen receptor (ER) signaling as most research is focused on understanding E2 and ER’s ability to enhance proliferative signals in breast cancers. Progesterone (P4) is important for normal mammary gland development, function and menstrual control. However, P4 and its receptors (PRs) in breast cancer etiology continue to be understudied and its role in breast cancer remains controversial. The Women’s Health Initiative (WHI) clinical trial clearly demonstrated the importance of progestogens in breast cancer development. P4 has historically been associated with classical-signaling through nuclear receptors, however non-classical P4 signaling via membrane receptors has been described. Progestogens have the ability to bind to nuclear and membrane receptors and studies have demonstrated that both can promote breast cancer cell proliferation and breast tumor growth. In this review, we attempt to understand the classical and non-classical signaling role of P4 in breast cancers because both nuclear and membrane receptors could become viable therapeutic options for breast cancer patients.
机译:随着大多数研究的重点是了解E2和ER在乳腺癌中增强增殖信号的能力,将雌激素(E2)和雌激素受体(ER)信号传导置于雌激素受体(ER)信号传播。黄体酮(P4)对于正常乳腺开发,功能和月经控制是重要的。然而,在乳腺癌病因中的p4及其受体(PRS)继续被解读,并且其在乳腺癌中的作用仍然存在争议。妇女的健康倡议(WHI)临床试验清楚地证明了孕激素在乳腺癌发展中的重要性。 P4历史上通过核受体与古典信号传导相关联,然而已经描述了通过膜受体的非典型P4信号传导。孕激素具有结合核和膜受体的能力,研究表明,两者都可以促进乳腺癌细胞增殖和乳腺肿瘤生长。在本综述中,我们试图了解乳腺癌中P4的经典和非古典信令作用,因为核和膜受体可能成为乳腺癌患者的可行治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号